We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
976
DELISTED
Ansys
ANSS
| $1.74M | ﹤0.01% |
4,966
-30,285
| -86% | -$9.92M |
2013 Q2
48 quarters
|
|
977
Moog Inc Class A
MOG.A
$11.6B
| $1.74M | ﹤0.01% |
9,632
-363
| -4% | -$63.6K |
2023 Q3
7 quarters
|
|
978
Jazz Pharmaceuticals
JAZZ
$13.9B
| $1.74M | ﹤0.01% |
16,402
+1,078
| +7% | +$117K |
2018 Q1
29 quarters
|
|
979
Sabesp
SBS
$22B
| $1.73M | ﹤0.01% |
406,303
| – | – |
2022 Q4
10 quarters
|
|
980
Establishment Labs
ESTA
$1.83B
| $1.73M | ﹤0.01% |
40,504
-1,433
| -3% | -$50K |
2024 Q3
3 quarters
|
|
981
iShares Core High Dividend ETF
HDV
$15.4B
| $1.71M | ﹤0.01% |
72,800
-4,225
| -5% | -$97.4K |
2022 Q2
12 quarters
|
|
982
Itron
ITRI
$3.71B
| $1.69M | ﹤0.01% |
12,827
-18,496
| -59% | -$2.09M |
2019 Q3
23 quarters
|
|
983
BlueLinx
BXC
$576M
| $1.68M | ﹤0.01% |
22,635
-52
| -0.2% | -$3.63K |
2019 Q4
22 quarters
|
|
984
KKR & Co 6.25% Series D Preferred Stock
KKR.PRD
$2.08B
| – | – |
0
| – | – |
2025 Q1
1 quarter
|
|
985
Sensata Technologies
ST
$6.01B
| $1.66M | ﹤0.01% |
55,296
+41,133
| +290% | +$1.01M |
2023 Q3
7 quarters
|
|
986
DELISTED
WNS Holdings
WNS
| $1.66M | ﹤0.01% |
+26,311
| New | +$1.58M |
2025 Q2
0 quarters
|
|
987
Moelis & Co
MC
$4.1B
| $1.66M | ﹤0.01% |
26,571
-5,852
| -18% | -$328K |
2025 Q1
1 quarter
|
|
988
Real REMAX Group Inc. Common Stock
REAX
$348M
| $1.63M | ﹤0.01% |
36,195
+30
| +0.1% | +$1.29K |
2024 Q3
3 quarters
|
|
989
Payoneer
PAYO
$2.42B
| $1.63M | ﹤0.01% |
237,526
+189,900
| +399% | +$1.29M |
2023 Q4
6 quarters
|
|
990
Apogee Enterprises
APOG
$862M
| $1.63M | ﹤0.01% |
40,038
-68
| -0.2% | -$2.81K |
2020 Q1
21 quarters
|
|
991
DT Midstream
DTM
$12.1B
| $1.61M | ﹤0.01% |
14,634
-41
| -0.3% | -$4.15K |
2021 Q3
15 quarters
|
|
992
Flowserve
FLS
$9B
| $1.6M | ﹤0.01% |
30,641
-5,367
| -15% | -$252K |
2016 Q2
36 quarters
|
|
993
Unum
UNM
$14.6B
| $1.6M | ﹤0.01% |
19,814
+745
| +4% | +$58.8K |
2015 Q1
41 quarters
|
|
994
PetMed Express
PETS
$26.4M
| $1.6M | ﹤0.01% |
481,434
+2,851
| +0.6% | +$10.2K |
2023 Q4
6 quarters
|
|
995
Ardagh Metal Packaging
AMBP
$2.79B
| $1.59M | ﹤0.01% |
371,400
-29,535
| -7% | -$107K |
2022 Q1
13 quarters
|
|
996
Avient
AVNT
$3.58B
| $1.59M | ﹤0.01% |
49,190
-16,476
| -25% | -$570K |
2014 Q2
44 quarters
|
|
997
Constellium
CSTM
$3.45B
| $1.59M | ﹤0.01% |
+119,249
| New | +$1.34M |
2025 Q2
0 quarters
|
|
998
United Natural Foods
UNFI
$2.91B
| $1.58M | ﹤0.01% |
67,689
+1,654
| +3% | +$43.1K |
2020 Q2
20 quarters
|
|
999
Ironwood Pharmaceuticals
IRWD
$623M
| $1.56M | ﹤0.01% |
2,177,038
+871,676
| +67% | +$684K |
2024 Q4
2 quarters
|
|
1000
Tenable Holdings
TENB
$4.33B
| $1.55M | ﹤0.01% |
45,928
-45,573
| -50% | -$1.48M |
2022 Q4
10 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.